opens new tab on Friday said it had struck a licensing deal worth ... well as royalties. Sanofi, one of the world's largest vaccine makers, will gain a license to co-sell Novavax's vaccine in ...
The vaccine maker said overnight that it has reached a licensing agreement ... As part of the deal, Sanofi will take a minority equity investment in Novavax. Write to Dean Seal at dean.seal@ ...
Novavax shares (NVAX) surged after the vaccine maker said it had struck a licensing deal worth up to $1.4 billion with Sanofi (SNY, FR:SAN). Novavax shares were up 133% in recent trading at $10.11.
Licensing agreement includes commercializing a combined Covid-19 and flu shot Sanofi and Novavax Inc. signed a licensing agreement that includes commercializing a combined Covid-19 and flu shot.
(Bloomberg) -- Novavax Inc. shares surged after the company signed a $1.2 billion licensing agreement ... receive tiered royalties on any vaccine sales, said Sanofi is also taking a minority ...
LONDON — Novavax, the beleaguered maker of a Covid-19 vaccine, just got a boost of its own. The French pharma company Sanofi on Friday said it had reached a licensing deal to sell Novavax’s ...
As part of the deal, Sanofi (SNY) will receive a license to co-commercialize Novavax's (NVAX) COVID-19 vaccine worldwide and a sole license to use the vaccine in combination with its flu vaccines.
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
The co-exclusive licensing agreement between the two pharmaceutical companies includes co-commercializing Novavax's COVID-19 vaccine and developing a combination vaccine for the flu and COVID-19.
Under the licensing agreement, Sanofi will pay Novavax $500 million upfront with up to $700 million in milestone payments, making the deal worth up to $1.2 billion. The agreement also gives Sanofi ...
Under the terms of the licensing deal, Novavax will receive an upfront ... and mid-single digit royalties for each additional Sanofi vaccine product developed under a non-exclusive license with ...